Evidence map›Paper›PMID 28994205›Full record

ArticleProteomics2017

Proteomics and Network Analyses Reveal Inhibition of Akt-mTOR Signaling in CD4

Ahmad F Karim, Obondo J Sande, Sara E Tomechko, Xuedong Ding, Ming Li, Sean Maxwell, Rob M Ewing, Clifford V Harding, Roxana E Rojas, Mark R Chance and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Ahmad F KarimDepartment of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Obondo J SandeDepartment of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Sara E TomechkoCenter for Proteomics & Bioinformatics, Case Western Reserve University, Cleveland, OH, USA.
Xuedong DingDepartment of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Ming LiCenter for Proteomics & Bioinformatics, Case Western Reserve University, Cleveland, OH, USA.
Sean MaxwellCenter for Proteomics & Bioinformatics, Case Western Reserve University, Cleveland, OH, USA.
Rob M EwingCentre for Biological Sciences, University of Southampton, Southampton, UK.
Clifford V HardingDepartment of Molecular Biology & Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Roxana E RojasDepartment of Molecular Biology & Microbiology, Case Western Reserve University, Cleveland, OH, USA.
Mark R ChanceCenter for Proteomics & Bioinformatics, Case Western Reserve University, Cleveland, OH, USA.
W Henry BoomDepartment of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Case Western Reserve University · USUniversity Hospitals of Cleveland · USSanofi (United States) · USUniformed Services University of the Health Sciences · USUniversity of Southampton · GB

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
Regulation of macrophages by Mycobacterium tuberculosisR01AI034343 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 1994 to 2017
$6.2M
HETEROGENEITY OF TCELLS IN M TUBERCULOSIS INFECTIONR01AI027243 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY · 1989 to 2016
$5.5M
MYCOBACTERIUM TUBERCULOSIS INFECTION IN THE LUNGR01HL055967 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY · 1995 to 2010
$4.2M
Proteogenomics of dysregulated protein interaction networks in MTB infectionR01HL106798 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI BOOM, W. HENRY, CHANCE, MARK R · 2010 to 2013
$2.8M
M. tuberculosis lipoprotein-TLR2 interactionsR01AI069085 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2007 to 2011
$1.9M
Role of TLR2 engagement on CD4+ T cells in immunity to M. tuberculosisR21AI099494 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROJAS, ROXANA E. · 2012 to 2013
$432k
NCI NIH HHS P30 CA043703NHLBI NIH HHS R01 HL055967NHLBI NIH HHS R01 HL106798NIAID NIH HHS P30 AI036219NIAID NIH HHS R01 AI027243NIAID NIH HHS R01 AI034343NIAID NIH HHS R01 AI069085NIAID NIH HHS R21 AI099494
6 · The paper itself

Abstract

Mycobacterium tuberculosis (Mtb) cell wall glycolipid mannose-capped lipoarabinomannan (ManLAM) inhibits CD4

Indexed as

Gene Regulatory NetworksAnimalsCD4-Positive T-LymphocytesCell CycleFemaleLipopolysaccharidesMannoseMass SpectrometryMiceMice, Inbred C57BLMycobacterium tuberculosisOncogene Protein v-aktProteomicsSignal TransductionTOR Serine-Threonine KinaseslipoarabinomannanLipopolysaccharidesMannoseOncogene Protein v-aktTOR Serine-Threonine KinasesAktCD4+ T-celllabel-free mass spectrophotometryManLAMmTORM. tuberculosis

Identifiers

PMID28994205
PMCPMC5725663
OpenAlexW2762052606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.